SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Corixa [CRXA] - cancer vaccines -- Ignore unavailable to you. Want to Upgrade?

To: Pseudo Biologist who wrote (66)3/20/2001 3:36:31 PM
From: Biomaven  Read Replies (2) | Respond to of 222
 
I do recall Rick raising early questions as to the comparative efficacy of the hot antibody and the cold antibody, and the company being fairly evasive on the issue.

One other warning sign in retrospect was the European Bexxar rights - when those were waived it was a wake-up call that we all apparently slept right through.

Finally, when we never got a good explanation of the "reformatting" fiasco, we should have been out of the stock.

So there were indeed some warning signs - the trouble is they were stacked up against very good clinical results.

I exited my final tranche last week, just missing this final debacle.

Peter



To: Pseudo Biologist who wrote (66)3/26/2001 10:50:21 AM
From: LLCF  Read Replies (1) | Respond to of 222
 
<Bexxar was the only thing worth getting excited about. >

So is Bexxar 'death' a certainty?

DAK


HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News